Efectividad anticoagulante de la warfarina en pacientes del hospital Teodoro Maldonado Carbo (HTMC), 1 de enero al 31 de octubre del 2016.

Abstract

At present moment there are several pathological conditions that demand anticoagulation during its treatment and prevention of long-term complications: cardiological, hematological, and neurological, among others. Warfarin is the oral anticoagulant drug archetype for this function. This drug acts on coagulation by inhibiting vitamin K-dependent coagulation factors.Depending on the pathology and the patient's condition, it has been estimated the degree of anticoagulation required in the patient to avoid both ischemic and hemorrhagic events. In most conditions, it is estimated that the appropriate therapeutic range to assess is the International Normalized Ratio (INR) is 2-3. There is a high risk of undesirable effects in patients undergoing continuous warfarin therapy because of the variability of patients' response to the drug. Therefore, it is not uncommon to find patients with inadequate controls. It is necessary to consider aspects that are directly related to the metabolism of the drug, modifying the patient's response such as: pre-existing pathology, comorbidities, drugs, diet, alcohol intake, among others. In this paper, we present a sample that demonstrates the anticoagulant effectiveness of warfarin, the main pathologies requiring anticoagulation with warfarin and the prevalence of comorbidities.